Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. - Wikidata - awgldk - TriplyDB

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

http://www.wikidata.org/entity/Q35751307

about

Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study.Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine.Diffusion weighted imaging evaluated the early therapy effect of tamoxifen in an MNU-induced mammary cancer rat model Antitumor efficacy of α-solanine against pancreatic cancer in vitro and in vivo Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models.

P2860

Q28077999-4DCA6988-8F9B-4359-BBB8-3C1584AAF7AD Q33775762-D3AE70D8-1C0A-4DFF-A543-21B86F1C470A Q33989940-E72B567D-470A-45F0-8390-A5C24499DAEE Q34229404-97CC0738-AA53-4A8A-BFA7-3F24F3798762 Q34657038-5EB4A5D4-C974-485A-B6B5-0561041B25D9 Q34735514-934DCD67-4FE2-481D-A64C-F3CDDF90F9AC Q35088276-00455225-359E-4E78-969E-743A6F7170C0 Q35970722-0C7E3FA8-7519-4C62-B85C-CC6E0FCA0085 Q35984544-9DF5244E-536B-4078-96A8-A2C0C3369B20 Q36917864-BB8169C8-4E1D-40D4-A585-2AE4356EE7E9 Q37416242-82AE776C-2741-4E22-AB2E-AEE2C7799323 Q38152999-58B384AF-1324-442F-8F18-7CA1C61E95D2 Q38820739-1F98AAAC-74B7-415B-8243-3C34498DA9D7

P2860

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

http://www.wikidata.org/entity/Q35751307

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

@ast

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

@en

type

label

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

@ast

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

@en

prefLabel

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

@ast

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

@en

P1433

Q35751307-5E7FC48B-6F99-4121-AAB0-63E3B6ED1DEF

P1476

Q35751307-367DA851-81A1-497D-B696-AE1B0F2B2656

P2093

Q35751307-0926CCF2-128C-44FB-ACD5-68445B44C429

Q35751307-1AB2B5B7-1395-40EE-B40D-5BFB397EDB69

Q35751307-39C79015-09E2-4382-9CC5-AC139927D792

Q35751307-3DC1BE95-BB3C-4695-87A6-6525D8B2EC16

Q35751307-3ECC30FD-3E6C-42CC-91B6-38931D9F1ABA

Q35751307-69AFC3AE-35C3-4ECE-9776-4DA7F958589B

Q35751307-721E8386-A7F4-4857-A890-BE4477D10E6C

Q35751307-A096207A-6747-4164-945F-852F76E0BC6B

Q35751307-D3B43E2D-5EED-4122-988D-1F865FE90D76

P2860

Q35751307-1D1B881E-09D5-466F-B57E-0AD1F0163287

Q35751307-2C2B7097-27E4-4F5F-905E-AAF95DFD71B2

Q35751307-2F237AD9-A217-47E5-9AE7-5E7EABF64004

Q35751307-3A912241-B99D-4727-BC0C-B7F579FADA81

Q35751307-4E77AB92-5CE8-427C-B19B-766685F06BA3

Q35751307-541FEAC3-2147-40CE-BA23-3BF321C51831

Q35751307-5716C1DD-B1DC-4770-93BB-75C859DBB848

Q35751307-5CBBA5F4-5F21-489C-84D2-85BD8EBC62C7

Q35751307-5DD42F18-4191-4B82-BA2A-24FF7BE14B02

Q35751307-631B257F-31F2-43E8-9C81-FEBFA93914C4

P304

Q35751307-FD6907CC-7682-46F7-BA82-61106E504E02

P31

Q35751307-467B02AE-3EB5-4D05-A88B-0A55261FDCD6

P356

Q35751307-F03C9A29-5634-4BCE-B288-209AD9BF6D34

P433

Q35751307-6D353E35-679F-4E8D-B0C8-3F2C9703B8B8

P478

Q35751307-54C39FD0-C69D-44BD-80B3-BADB4781393E

P577

Q35751307-EAF893B8-C338-4E5E-A921-EA891244545D

P5875

Q35751307-5E98968A-E5C6-41B9-9D21-47F66430BFB1

P698

Q35751307-FE8640E5-869C-43E0-A405-C5C6B2EE0F85

P932

Q35751307-59E3FC68-CC81-48A8-BF69-759DC4DFC6B7

P356

1535-7163.MCT-11-0581

P1433

Molecular Cancer Therapeutics

P1476

Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

@en

P2093

Cecil R Stockard

http://www.w3.org/2001/XMLSchema#string

Christopher J Rigell

http://www.w3.org/2001/XMLSchema#string

Guihua Zhai

http://www.w3.org/2001/XMLSchema#string

Heidi R Umphrey

http://www.w3.org/2001/XMLSchema#string

Hyunki Kim

http://www.w3.org/2001/XMLSchema#string

Kurt R Zinn

http://www.w3.org/2001/XMLSchema#string

Naomi S Fineberg

http://www.w3.org/2001/XMLSchema#string

Samir Rana

http://www.w3.org/2001/XMLSchema#string

Sharon L Samuel

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

CD95 promotes tumour growth

Early detection of pancreatic cancer: why, who, and how to screen

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Cancer statistics, 2009

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy

P304

405-415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-11-0581

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51895889

http://www.w3.org/2001/XMLSchema#string

P698

22203731

http://www.w3.org/2001/XMLSchema#string

P932

3277644

http://www.w3.org/2001/XMLSchema#string